NurExone Biologic Inc.
NRX.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -10.01% | -8.54% | -23.68% | 5.66% | -43.71% |
| Total Depreciation and Amortization | -2.33% | 10.26% | 116.67% | 38.46% | -13.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.00% | -6.01% | 5.38% | -1.25% | 1,233.33% |
| Change in Net Operating Assets | 26.19% | 159.89% | -672.45% | -19.67% | 120.96% |
| Cash from Operations | -8.22% | 43.17% | -112.10% | 5.98% | 40.61% |
| Capital Expenditure | 93.75% | 30.43% | 84.72% | -393.44% | 74.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Investing | 93.75% | 28.89% | 85.05% | -323.94% | 70.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 66.67% | 57.14% | 12.50% | -14.29% | 12.50% |
| Issuance of Common Stock | 74.26% | -37.47% | 66.48% | 5,746.67% | -99.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -427.18% | 983.33% | -- |
| Cash from Financing | 74.73% | 414.12% | -85.94% | 2,761.36% | -99.00% |
| Foreign Exchange rate Adjustments | 3,075.00% | 98.18% | -10,900.00% | -107.41% | 22.73% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 671.43% | 93.86% | -1,421.01% | 115.86% | -132.06% |